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Background: Perfluoroalkyl substances (PFAS) are suggested to affect human fecundity through longer time to
pregnancy (TTP). We studied the relationship between four abundant PFAS and TTP in pregnant women from
Greenland, Poland and Ukraine representing varying PFAS exposures and pregnancy planning behaviors.
Methods: We measured serum levels of perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS),
perfluorohexane sulfonic acid (PFHxS) and perfluorononanoic acid (PFNA) in 938 women from Greenland (448
women), Poland (203 women) and Ukraine (287 women). PFAS exposure was assessed on a continuous logarithm
transformed scale and in country-specific tertiles. We used Cox discrete-time models and logistic regression to
estimate fecundability ratios (FRs) and infertility (TTP >13 months) odds ratios (ORs), respectively, and 95%
confidence intervals (CI) according to PFAS levels. Adjusted analyses of the association between PFAS and TTP were
done for each study population and in a pooled sample.
Results: Higher PFNA levels were associated with longer TTP in the pooled sample (log-scale FR = 0.80; 95% CI
0.69-0.94) and specifically in women from Greenland (log-scale FR = 0.72; 95% CI 0.58-0.89). ORs for infertility were
also increased in the pooled sample (log-scale OR = 1.53; 95% CI 1.08-2.15) and in women from Greenland (log-scale
OR = 1.97; 95% CI 1.22-3.19). However, in a sensitivity analysis of primiparous women these associations could not be
replicated. Associations with PFNA were weaker for women from Poland and Ukraine. PFOS, PFOA and PFHxS were not
consistently associated with TTP.
Conclusions: Findings do not provide consistent evidence that environmental exposure to PFAS is impairing female
fecundity by delaying time taken to conceive.
Keywords: Fecundity, Perfluorinated compounds, Infertility, Persistent environmental pollutantsPerfluoroalkyl substances (PFAS) (also referred to as
perfluorinated compounds) are used in a wide range of
industrial and consumer products. These man-made
contaminants are biopersistent with half-lives reported
from three to nine years and have been detected in
many human populations [1,2]. The main route of hu-
man exposure is from intake of contaminated food and
drinking water [3,4] However, house dust may also be
contributing to PFAS exposure [5]. Although some
PFAS, like perfluorooctane sulfonate (PFOS), have been
phased out since 2000, the compounds that already* Correspondence: jpb@bbh.regionh.dk
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unless otherwise stated.exist in the environment may potentially continue to
affect human health for many years to come because of
their high persistency [6]. Furthermore, new PFAS have
been introduced and their possible impact on human
health has not been thoroughly investigated.
Toxicological effects of PFAS have mainly been stud-
ied in experimental animal models and include repro-
ductive impairments [7-9]. Health effects in humans are
not well-established [10,11]. Four previous studies have
addressed the association between PFAS and couple fe-
cundity in humans measured by time to pregnancy (TTP).
A study from Denmark examined PFOS and perfluoro-
octanoic acid (PFOA) exposure levels in blood samples of
pregnant women and found reduced fecundability ratios
and increased infertility in women with PFOS and PFOAtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tribution corresponding to plasma concentrations of
26.6 ng/ml and 4.9 ng/ml, respectively [12]. These asso-
ciations were confirmed when the authors restricted the
analysis to pregnant primiparous women [13]. A case–
control study from Norway found increased odds of
subfecundity (TTP >12 months) in women with high
exposure to PFOS and PFOA. However, these findings
were not confirmed when restricting to primiparous
women [14]. A prospective study from the US assessed
the relationship between seven PFAS as well as other
persistent environmental pollutants and couple fecundity
in pregnancy planners. Overall they did not find much
support for an association between PFAS exposure and
TTP [15]. Also, a Danish prospective study of pregnancy
planners found no association between seven PFAS and
TTP despite relatively high exposure levels [16].
On the basis of the existing literature it is therefore
unresolved whether environmental exposure to PFAS
may affect human fecundity. This study is addressing the
association between exposure to PFAS and time taken to
conceive and is distinguished from earlier studies by in-
clusion of three study populations from three geograph-
ical regions which provides opportunities to examine
consistency of findings across different populations stud-
ied according to uniform study protocols. Moreover, this
is the first study taking PFAS exposure of both partners
into account. The study included measurements of the
four PFAS found in highest concentrations in humans;
PFOA, PFOS, perfluorohexane sulfonic acid (PFHxS)
and perfluorononanoic acid (PFNA) [10].
Methods
Study populations
This study is based on the INUENDO cohort including
a total of 1710 pregnant women from Greenland, Poland
(Warsaw) and Ukraine (Kharkiv) enrolled during ante-
natal care visits between May 2002 and February 2004.
The participants were at least 18 years old and born in
the country of study. They were asked to complete a
questionnaire and give a blood sample at enrolment.
The participation rates were 90% (598/665) in Greenland,
68% (472/690) in Poland, and 26% (640/2478) in Ukraine.
One of the reasons that a large number of pregnant
women refused to participate in Ukraine was concern that
the collection of a blood sample (altogether 35 ml whole
blood) would imply a health risk [17]. An analysis of
demographic and reproductive data in a large sample of
women that declined participation did not indicate that
the Ukranian sample is a select group [17]. The
INUENDO study population has been described in de-
tail elsewhere [17].
A group of 437 women became pregnant despite use
of birth control and thus had no eligible TTP, and for131 women we had no information regarding TTP. A
further 204 women did not provide a blood sample.
Thus, the final cohort of women providing both ques-
tionnaire data and a blood sample comprised 938
women with 448, 203 and 287 women from Greenland,
Poland and Ukraine, respectively.
Time to pregnancy data
Information on the time taken to conceive the current
pregnancy was obtained by the following two questions:
(1) Leading up to this pregnancy, when was it that you
started having sexual intercourse without using any
birth control to prevent pregnancy?” Month:______
Year:______. We now call this the “STARTING TIME”.
(2) How long was it from that “STARTING TIME” until
you became pregnant? (The date you became pregnant
is the date you conceived) How long? Weeks:______
and/or Months:______ and/or Years: ______. Further
details are provided in [17].
Analysis of PFAS
The laboratory analysis of serum concentrations of
PFOA, PFOS, PFHxS and PFNA has been described in
detail elsewhere [18,19]. In short, PFAS were analyzed
with liquid chromatography tandem mass spectrometry.
Limits of detection (LOD) were the following: PFOA
0.04 ng/ml, PFOS 0.2 ng/ml, PFHxS 0.02 ng/ml and
PFNA 0.03 ng/ml. For all four PFAS the detection fre-
quency was 100%. The reproducibility of the method
was determined as the coefficient of variation of dupli-
cate samples analyzed on different days and found to be
6% for PFOA, 5% for PFOS, 8% for PFHxS and 9% for
PFNA. The analyses of PFOS and PFOA are part of the
Round Robin inter-comparison program (Professor Dr.
med. Hans Drexler, Institute and Out-Patient Clinic for
Occupational, Social and Environmental Medicine, Uni-
versity of Erlangen-Nuremberg, Germany) with results
within the tolerance limits.
Statistical analyses
Each study population was studied separately where all
measures of female serum concentrations of PFAS were
i) categorized into country-specific tertiles with the low-
est category for each country serving as reference cat-
egory, and ii) handled on a continuous logarithm
transformed scale. We also studied the association be-
tween TTP and PFAS on the continuous log-scale for a
pooled sample consisting of all 938 study participants.
We calculated fecundability ratios (FRs) with 95% confi-
dence intervals (CIs) using a discrete-time Cox regres-
sion model that handled the underlying time scale – the
TTP in months – as a discrete scale. The FR represents
the probability of conceiving during a time period (e.g.,
one month or one menstrual cycle) within one group
Table 1 Characteristics of the cohort according to body
mass index, age, number of previous childbirths, smoking
status, education and gestational week of blood sampling
Greenland Poland Ukraine
Maternal BMI n (%) n (%) n (%)
<20 56 (13) 61 (30) 93 (32)
20-24 224 (50) 122 (60) 156 (54)
25+ 164 (37) 17 (8) 37 (13)
Missing 4 (1) 3 (1) 1 (0)
Maternal age (yrs)
<25 224 (50) 28 (14) 200 (70)
25-29 93 (21) 134 (66) 61 (21)
30+ 117 (26) 41 (20) 22 (8)
Missing 14 (3) 0 (0) 4 (1)
Previous childbirths
0 138 (31) 187 (92) 227 (79)
1 138 (31) 12 (6) 52 (18)
2+ 169 (38) 1 (0) 4 (1)
Missing 3 (1) 3 (1) 4 (1)
Smoking status
Non-smoker 118 (26) 167 (82) 222 (77)
Smoker 330 (74) 36 (18) 65 (23)
Maternal Education
Left school at age ≤17 187 (42) 0 (0) 87 (30)
Left school at age ≥18 44 (10) 6 (3) 77 (27)
Post school training 162 (36) 18 (9) 90 (31)
University degree 7 (1) 157 (77) 0 (0)
Other or unknown 48 (11) 22 (11) 33 (12)
Time from last menstrual bleeding to interview and blood sampling
(weeks)
01-20 141 (31) 1 (0) 112 (39)
21-30 151 (34) 35 (17) 61 (21)
31-42 128 (29) 152 (75) 89 (31)
Missing 28 (6) 15 (7) 25 (9)
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stead of censoring after 12 months, TTP was censored
after 13 months in order to take digit preference into ac-
count (proportionally more women recall TTPs of
12 months compared to 11 and 13 months). All FR ana-
lyses were adjusted for maternal age (<25, 25–29, 30+
years), self-reported smoking status (yes, no), parity sta-
tus (primiparous, 1, 2+ children), maternal body mass
index (BMI, <20, 20–24, 25+) and gestational week at
interview and blood sampling (gestational week 1–20,
21–30, 31+). In the pooled analysis an additional adjust-
ment was made for country. Odds ratios (ORs) and 95%
CIs were calculated in a logistic regression analysis in
which women with TTPs >13 months were categorized
as infertile (despite they eventually became pregnant),
while women with TTPs ≤13 months were fertile. The
OR analysis was adjusted for the same covariates as in
the Cox regression model. Spearman correlation coeffi-
cients (rS) were used to assess country-specific correla-
tions between PFAS in women and correlations between
levels in men (see below) and women. Two-sided statis-
tical tests were applied and P-values <0.05 and 95% CIs
excluding unity were considered statistically significant.
The statistical analysis was conducted in SAS statistical
software version 9.3.
In a number of supplementary analyses we tested the
robustness of the main findings. I) We restricted to
primiparous women and calculated FRs and infertility
ORs based on the original PFAS tertile levels used in the
main analysis. Restriction to primiparous women was
considered essential to bypass reverse causality that may
be introduced by the association between prolonged
time to pregnancy and increasing PFAS levels with time
after delivery [20,21] II) We analyzed the association be-
tween male serum levels of PFAS and couple TTP for
401 male spouses of the female participants who also
provided a blood sample (160 men from Greenland, 146
men from Poland, and 95 men from Ukraine). The ana-
lysis concerning male PFAS levels was adjusted for pa-
ternal age (<25, 25–29, 30+ years), paternal BMI (<20,
20–24, 25+) and maternal age (<25, 25–29, 30+ years).
In the pooled sample we additionally adjusted for coun-
try. FRs were based on couple TTP according to
country-specific PFAS tertiles and the continuous log-
scale of PFAS exposure.
Ethical approval
The study was approved by the relevant scientific ethical
committees in Greenland, Poland and Ukraine and all
participants signed an informed consent.
Results
The median TTP was 4 [interquartile range (IQR) 2–8],
4 (IQR 2–9) and 5 (IQR 3–13) months for women fromGreenland, Poland and Ukraine, respectively. The pro-
portion of infertile couples (TTP >13 months) was 14%
in Greenland, 16% in Poland and 20% in Ukraine. The
median gestational week of enrolment and blood sam-
pling was week 24 (IQR 18–32) for Greenland, 33 (IQR
31–35) for Poland, and 23 (IQR 12–33) for Ukraine.
Women from Greenland generally had higher BMI,
more children and were more likely to smoke compared
to women from Poland and Ukraine. The educational level
was higher for women from Poland than for women from
Greenland and Ukraine. Women from Ukraine were
generally younger than women from Greenland and
Poland (Table 1). The coefficient of correlation for
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in Poland to 0.69 (95% CI 0.65-0.73) in Ukrania.
Concentrations of PFAS in women from Greenland,
Poland and Ukraine
The median levels of serum PFAS in women from
Greenland, Poland and Ukraine are presented in Table 2.
Correlations between PFAS
PFOS was correlated with PFOA (rS = 0.50) and PFNA
(rS = 0.74) in women from Greenland. In women from
Poland, PFOS was correlated with PFOA (rS = 0.52) and
PFNA (rS = 0.50) while PFOA and PFNA also were cor-
related (rS = 0.69). Similar correlations were found for
women from Ukraine (PFOS and PFOA, rS = 0.52; PFOS
and PFNA, rS = 0.55; PFOA and PFNA, rS = 0.52). PFHxS
was to a lesser extent correlated with the other PFAS
(from rS = 0.16 for PFHxS and PFNA in Ukraine to rS =
0.38 for PFHxS and PFOS in Greenland). We also
assessed correlations of PFAS in 152, 145 and 86 couples
from Greenland, Poland and Ukraine, respectively, for
whom we had a blood sample available from both the
man and woman. In Greenland PFNA levels in men and
women were correlated (rS = 0.52), PFOS (rS = 0.22) and
PFHxS (rS = 0.22) were weakly correlated, while PFOA
levels were not (rS = 0.06). In Poland PFNA levels in
men and women were also correlated (rS = 0.48), while
the other PFAS were less strongly correlated (PFOA rS =
0.29, PFOS rS = 0.25, and PFHxS rS = 0.14). In Ukraine
PFAS levels in men and women were generally notTable 2 Overall and country-specific median serum levels of P
Ukraine and exposure ranges in the country specific tertiles
Overall
















PFAS perfluoroalkyl substances.correlated (PFOA rS = 0.20; PFOS rS = −0.09; PFHxS rS =
0.13; PFNA rS =0.14).
PFAS and fecundability and infertility ratios
PFOA
PFOA was not associated with FRs (Table 3) or infertility
ORs (Table 4) in women specifically from Greenland,
Poland and Ukraine or in the pooled sample (continuous
log-scale FR = 1.04, 95% CI 0.87-1.25 and OR = 1.11,
95% CI 0.74-1.66).
PFOS
Higher PFOS levels were associated with slightly re-
duced FRs in women from Greenland (continuous log-
scale FR = 0.83, 95% CI 0.64-1.07) (Table 3) and in-
creased odds for infertility in each of the three countries
(ORs of 1.82, 1.92 and 1.22 for high versus low PFOS in
women from Greenland, Poland and Ukraine, respect-
ively) (Table 4). However, none of these associations
were statistically significant and in the pooled sample
there was no strong support for a dose–response rela-
tionship between higher PFOS levels and a reduced FR
(continuous log-scale FR = 0.90, 95% CI 0.76-1.07) or an
increased infertility OR (continuous log-scale OR = 1.39,
95% CI 0.93-2.07).
PFHxS
No association was found between levels of PFHxS and
FRs (Table 3) or infertility ORs (Table 4) in women from


















Table 3 Fecundability ratios according to female serum concentrations of PFAS
PFOA PFOS PFHxS PFNA
Greenland N FR (95% CI) FR (95% CI) FR (95% CI) FR (95% CI)
Low 150 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Medium 149 0.95 (0.72, 1.26) 0.80 (0.60, 1.05) 1.05 (0.79, 1.38) 0.76 (0.58, 1.00)
High 149 0.87 (0.65, 1.18) 0.80 (0.60, 1.05) 0.90 (0.68, 1.19) 0.71 (0.54, 0.94)
Continuous log-scale 448 0.97 (0.73, 1.27) 0.83 (0.64, 1.07) 0.97 (0.78, 1.20) 0.72 (0.58, 0.89)
Poland
Low 68 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Medium 68 0.94 (0.62, 1.42) 0.87 (0.57, 1.33) 0.86 (0.57, 1.30) 0.94 (0.62, 1.41)
High 67 1.08 (0.71, 1.64) 0.90 (0.60, 1.37) 0.94 (0.62, 1.42) 1.31 (0.87, 1.98)
Continuous log-scale 203 1.21 (0.79, 1.84) 0.94 (0.58, 1.50) 0.90 (0.65, 1.24) 1.35 (0.93, 1.95)
Ukraine
Low 96 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Medium 96 1.12 (0.78, 1.59) 0.89 (0.62, 1.27) 0.85 (0.59, 1.23) 0.79 (0.55, 1.12)
High 95 1.04 (0.72, 1.51) 0.93 (0.64, 1.34) 1.11 (0.78, 1.58) 0.88 (0.62, 1.26)
Continuous log-scale 287 1.20 (0.87, 1.67) 1.06 (0.78, 1.45) 1.05 (0.84, 1.31) 0.74 (0.53, 1.04)
Pooled sample
Continuous log-scale 938 1.04 (0.87, 1.25) 0.90 (0.76, 1.07) 0.97 (0.85, 1.11) 0.80 (0.69, 0.94)
FRs are presented in country-specific tertiles and according to a continuous logarithm-transformed scale.
CI confidence intervals, FR fecundability ratio, N number of women, PFAS perfluoroalkyl substances.
The FR analyses are adjusted for parity, gestational week of blood sampling, smoking status, maternal age and BMI. In addition the pooled analysis is adjusted
for country.
Table 4 Infertility odds ratios according to female serum concentrations of PFAS
N PFOA PFOS PFHxS PFNA
Greenland n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI)
Low 150 18 1 (Reference) 14 1 (Reference) 20 1 (Reference) 12 1 (Reference)
Medium 149 22 1.30 (0.66, 2.54) 23 1.73 (0.85, 3.49) 18 0.90 (0.45, 1.76) 23 1.95 (0.95, 3.99)
High 149 22 1.57 (0.76, 3.25) 25 1.82 (0.90, 3.67) 24 1.22 (0.64, 2.36) 27 2.15 (1.05, 4.42)
Continuous log-scale 448 62 1.20 (0.61, 2.37) 62 1.74 (0.97, 3.13) 62 0.99 (0.59, 1.65) 62 1.97 (1.22, 3.19)
Poland
Low 68 10 1 (Reference) 7 1 (Reference) 10 1 (Reference) 13 1 (Reference)
Medium 68 12 1.25 (0.50, 3.13) 13 1.93 (0.72, 5.18) 13 1.52 (0.60, 3.84) 11 0.92 (0.38, 2.22)
High 67 11 1.41 (0.55, 3.61) 13 1.92 (0.72, 5.14) 10 1.07 (0.41, 2.80) 9 0.65 (0.26, 1.66)
Continuous log-scale 203 33 1.11 (0.44, 2.80) 33 2.06 (0.69, 6.12) 33 1.05 (0.50, 2.20) 33 0.74 (0.32, 1.72)
Ukraine
Low 96 19 1 (Reference) 18 1 (Reference) 17 1 (Reference) 16 1 (Reference)
Medium 96 16 0.66 (0.30, 1.45) 20 1.51 (0.70, 3.26) 26 1.37 (0.66, 2.85) 22 1.39 (0.65, 2.97)
High 95 23 1.21 (0.57, 2.58) 20 1.22 (0.56, 2.65) 15 0.61 (0.27, 1.38) 20 1.17 (0.54, 2.53)
Continuous log-scale 287 58 0.79 (0.40, 1.54) 58 0.77 (0.41, 1.43) 58 0.76 (0.47, 1.24) 58 1.26 (0.66, 2.40)
Pooled sample
Continuous log-scale 938 153 1.11 (0.74, 1.66) 153 1.39 (0.93, 2.07) 153 0.99 (0.73, 1.33) 153 1.53 (1.08, 2.15)
CI confidence intervals, N number of women, OR odds ratio, PFAS perfluoroalkyl substances.
The OR analyses are adjusted for parity, gestational week of blood sampling, smoking status, maternal age and BMI.
In addition the pooled analysis is adjusted for country.
FRs are presented in country-specific tertiles and according to a continuous logarithm-transformed scale.
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0.99, 95% CI 0.73-1.33).PFNA
Women from Greenland with higher levels of PFNA had
reduced FRs (medium PFNA: FR = 0.76, 95% CI 0.58-
1.00; high PFNA: FR = 0.71, 95% CI 0.54-0.94) compared
to women with low levels of PFNA (Table 3). Although
not statistically significant, women from Ukraine with
medium (FR = 0.79, 95% CI 0.55-1.12) and high levels
(FR = 0.88, 95% CI 0.62-1.26) of PFNA also had reduced
FRs. In the pooled sample, women with higher PFNA
levels had significantly reduced FRs (continuous log-
scale FR = 0.80, 95% CI 0.69-0.94) (Table 3). Higher
PFNA levels were also associated with increased odds
for infertility in women from Greenland (medium PFNA:
OR = 1.95, 95% CI 0.95-3.99; high PFNA: OR = 2.15, 95%
CI 1.05-4.42) and in the pooled sample (continuous log-
scale OR = 1.53, 95% CI 1.08-2.15) (Table 4). In contrast,
we found no association between PFNA and FRs or in-
fertility ORs in women from Poland.Supplementary findings
In a sensitivity analysis restricted to primiparous women
(59% of the women were primiparous), the association
between PFNA and the FR in Greenland became weaker
(continuous log-scale FR = 0.87, 95% CI 0.60-1.28) and
in the pooled sample it became null (continuous log-
scale FR = 0.99, 95% CI 0.80-1.22). For PFOA we found a
statistically significant association between higher levels
and increased FRs in women from Ukraine (continuous
log-scale FR = 1.46, 95% CI 1.02-2.08) and in the pooled
sample (continuous log-scale FR = 1.31, 95% CI 1.03-
1.68). For levels of PFOS and PFHxS no associations
were found with the FRs for primiparous women (Add-
itional file 1: Table S1). Regarding the OR for infertility
in primiparous women none of the four PFAS were asso-
ciated with an increased risk of infertility in the pooled
sample (Additional file 2: Table S2). Furthermore, no
country-specific associations were found between PFOA,
PFOS, PFHxS and PFNA and infertility ORs in primipar-
ous women. However, these analyses were based on a
limited number of cases.
In addition to the female blood samples, we had blood
samples from a subset of 401 male spouses. For PFOA,
PFOS and PFHxS there was no consistent association
between higher exposure levels in men and prolonged
TTP (Additional file 3: Table S3). However, for higher
levels of PFNA the FRs were reduced in men from
Greenland (continuous log-scale FR = 0.70, 95% 0.50-
0.99) and Ukraine (continuous log-scale FR = 0.60, 95%
CI 0.33-1.10). In contrast, we found that higher levels of
PFNA was associated with an increased FR in men fromPoland (continuous log-scale FR = 1.48, 95% CI 0.86-
2.56).
Discussion
We studied the association between serum concentra-
tions of the four most abundant PFAS and couple fe-
cundity as measured by time taken to conceive
pregnancies The study populations from Greenland,
Poland and Ukraine represented populations with vary-
ing PFAS exposure levels and pregnancy planning cul-
tures. Women had on average a 20% reduced chance of
achieving pregnancy during one month and a 53% in-
creased risk of infertility per unit increase in PFNA ex-
posure on the log-scale. However, a sensitivity analysis
of primiparous women did not unambiguously support
that higher levels of PFNA are associated with longer
TTP. Also, male spouses with higher levels of PFNA had
longer couple TTP. PFOS was less consistently associ-
ated and PFOA and PFHxS were not associated with
TTP.
Four previous studies have assessed the association be-
tween female serum levels of PFAS and female fecundity.
Two of these studies involved women from Denmark,
but found conflicting results. In a study from 2009 on
1240 women, Fei et al. showed that women with expos-
ure levels of PFOS and PFOA above the 25th percentile
had longer TTP than women with exposure levels below
the 25th percentile [12]. Specifically, the chance of con-
ceiving during one time period was approximately re-
duced by 30-40% for women with exposures above the
lowest quartile of PFOS and PFOA. The study was based
on blood samples and TTP information collected during
pregnancy. In contrast, in 2012 Vestergaard et al. did
not find any association between TTP and eight PFAS
including PFOA, PFOS, PFHxS and PFNA in a prospect-
ive study based on 222 first pregnancy planners [16]. In
that study women were categorized according to PFAS
levels above or below the median concentrations. The
median concentrations of PFOA (approximately 6 ng/
ml) and PFOS (approximately 35 ng/ml) were almost
identical in these two Danish studies and at levels higher
than those found in the present study in Greenland
(PFOA 1.8 ng/ml, PFOS 20.3 ng/ml), Poland (PFOA
2.7 ng/ml, PFOS 8.0 ng/ml), and Ukraine (PFOA 0.9 ng/
ml, PFOS 4.9 ng/ml). In a Norwegian study from 2012
on 910 women, Whitworth et al. found increased odds
for subfecundity in parous women with high levels of
PFOS and PFOA [14], but they found no association for
primiparous women. The median concentrations of
PFOS and PFOA were 14 ng/ml and 2 ng/ml, respect-
ively, in the Norwegian study. In an American study
from 2013 on 501 couples, Buck Louis et al. looked at
couple fecundity in women from Michigan and Texas in
relation to various persistent environmental pollutants
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PFAS in that study were low compared to other studies,
and perfluorooctane sulphonamide (PFOSA) was the
only PFAS that was negatively associated with couple fe-
cundity. However, in 90% of the analyzed serum samples
the level of PFOSA was below the detection limit.
Pregnancy and breastfeeding are two of the major de-
terminants of female PFAS serum concentrations. Mater-
nal PFAS levels are reduced during pregnancy because of
the dilution effect of an increased blood volume, and levels
are inversely associated with the duration of breastfeeding
because of transfer from mother to child [20,21]. In parous
women, the serum PFAS concentration increases with the
time since the last pregnancy and breastfeeding period.
Parous women with longer TTP for a current pregnancy
may therefore be recorded with higher levels of PFAS than
women with shorter inter-pregnancy intervals if the blood
sample is collected during pregnancy. Thus, including par-
ous women may introduce reverse causality between in-
creased PFAS levels and prolonged TTP [16]. The large
majority of participants from Poland and Ukraine were
primiparous, but of the women from Greenland only 118
(31%) were first-time mothers. When we restricted the
analyses to these primiparous women the association with
PFNA practically disappeared.
Substantial differences were found between the study
populations from Greenland, Poland and Ukraine in ex-
posure levels of PFOS with median levels at concentra-
tions four times higher in women from Greenland than
from Ukraine. Also, for PFOA we found large exposure
differences with women from Poland exposed to almost
three times higher levels of PFOA than women from
Ukraine. In contrast, we found that exposure levels of
PFNA and PFHxS were similar in the three study popu-
lations. Thus, the lack of association between PFNA and
TTP in women from Poland cannot be explained by
lower exposure levels in these women.
TTP is a measure that reflects both the male and fe-
male reproductive capability as well as the early survival
of the fetus. So, the TTP in itself does not indicate if a
delayed conception is caused by male or female factors.
Moreover, in Greenland a close correlation was found
between levels of PFNA in women and men (rS = 0.52),
and couple TTP was similarly associated with female
serum levels of PFNA as with male serum levels of PFNA.
Although numerous studies in experimental animals
documents toxic effects of PFAS on several organ sys-
tems, there are no animal experimental data that directly
demonstrates effects on male or female fecundity and
possible mechanisms remain speculative [7,8]. Also, it is
not clear how PFAS might interfere with human fecund-
ity For instance disturbance of the menstrual cycle [22]
and risk of miscarriage [23,24] is not clearly related to
PFAS exposure. On the other hand there is limitedevidence that some PFAS are associated with reduced
semen quality [19]. This is the first study to examine TTP
in relation to both male and female PFAS exposure.
The study has a number of limitations that need con-
sideration. The time window of interest is from the time
of the first pregnancy attempt onwards, and our meas-
urement of PFAS levels during pregnancy may not be
representative for this period. Especially the transplacen-
tal transfer from mother to child and dilution because of
increased blood volume seem to impact the serum con-
centrations of PFAS in pregnancy [6]. We adjusted for
the gestational week of blood sampling, but still we can-
not exclude the possibility of non-differential misclassifi-
cation especially in women from Poland who had blood
samples collected late in pregnancy (median collection
time being gestational week 33). Furthermore, women
who failed to conceive or had an early miscarriage were
not included in the study. Delayed time to pregnancy be-
cause of miscarriage caused by PFAS exposure would
not be detected. Only women who plan or partly plan a
pregnancy can report a TTP and those who become
pregnant despite use of birth control have no eligible
TTP value.
Couple fecundity is the chance to conceive during one
menstrual cycle, and group-based TTP information from
a large sample of couples might provide a good appro-
ximation of fecundity in relevant groups of interest.
However, several determinants are important for the
comparability of TTP and couple fecundity. Couples
have to stop using birth control and start attempting
pregnancy at an exact time-point with regular unprotected
intercourse for the TTP to be a valid measure of fecundity.
Obviously, cultural and possibly behavioural differences
regarding pregnancy planning exist between the three
study populations [17] that might affect this approxima-
tion of the TTP as a measure of couple fecundity. Never-
theless, this study does not support a role of PFOA, PFOS
and PFHxS on human fecundity. For PFNA we found that
women with higher levels took longer time to achieve
pregnancy and had an increased risk of infertility than
women with lower exposure levels. However, this associ-
ation was not consistently found in all three study popula-
tions despite similar exposure levels, and generally the
analysis of primiparous women did not support an associ-
ation between PFAS and TTP.Additional files
Additional file 1: Table S1. Fecundability ratios in primiparous women
according to female serum concentrations of PFAS. FRs are presented
overall and specifically for Greenland, Poland and Ukraine. The tertiles are
based on the PFAS limits in the main analysis.
Additional file 2: Table S2. Infertility odds ratios according to female
serum concentrations of PFAS in primiparous women. FRs are presented
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transformed scale.
Additional file 3: Table S3. Fecundability ratios according to male
serum concentrations of PFAS. FRs are presented in country-specific
tertiles and according to a continuous logarithm-transformed scale.
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